Altimmune, Inc.ALTNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank36
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-3.28
↓ 89% vs avg
Percentile
P36
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
-1.74
Historical baseline
PeriodValueYoY Change
2025-3.28+34.7%
2024-5.03+4.8%
2023-5.28+32.6%
2022-7.84-299.7%
2021-1.96+57.3%
2020-4.60-427.5%
2019-0.87-242.3%
20180.61+289.0%
2017-0.32-102.9%
201611.21-